MELITAC 12.1

MELITAC 12.1 is a synthetic peptide cancer vaccine designed to stimulate immune responses against melanoma. It consists of an emulsion containing a mixture of 12 class I MHC-restricted melanoma peptides and a class II MHC-restricted tetanus toxoid helper peptide, formulated with the adjuvant Montanide ISA-51[1][4]. The vaccine aims to induce CD8+ T cell responses targeting multiple melanoma antigens, thereby enhancing anti-tumor immunity[5]. It has been studied in combination with immunostimulatory agents such as toll-like receptor agonists (e.g., polyICLC) and IDO1 inhibitors (e.g., epacadostat)[2][5]. The primary indication is for the treatment of advanced or high-risk melanoma, including cutaneous malignant and mucosal subtypes[3][6]. Initial development was by Oncovir; later development has involved Incyte Corporation and academic centers such as the University of Virginia[2][3][6].

Other names

MELITAC 12.1 peptide vaccineMELITAC12.1 peptide vaccineMELITAC-12.1 peptide vaccinemultipeptide melanoma vaccine